PEDIATRIX MEDICAL GROUP INC (MD) Stock Fundamental Analysis
USA - NYSE:MD - US58502B1061 - Common Stock
23.05 USD
-0.1 (-0.43%)
We assign a fundamental rating of 5 out of 10 to MD. MD was compared to 100 industry peers in the Health Care Providers & Services industry. MD has only an average score on both its financial health and profitability. A decent growth rate in combination with a cheap valuation! Better keep an eye on MD. These ratings would make MD suitable for value investing!
1. Profitability
1.1 Basic Checks
In the past year MD was profitable.
MD had a positive operating cash flow in the past year.
In multiple years MD reported negative net income over the last 5 years.
Each year in the past 5 years MD had a positive operating cash flow.
1.2 Ratios
The Return On Assets of MD (7.37%) is better than 89.00% of its industry peers.
MD has a better Return On Equity (18.21%) than 84.00% of its industry peers.
MD's Return On Invested Capital of 10.25% is amongst the best of the industry. MD outperforms 81.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for MD is in line with the industry average of 9.40%.
The 3 year average ROIC (7.83%) for MD is below the current ROIC(10.25%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.37% | ||
| ROE | 18.21% | ||
| ROIC | 10.25% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
1.3 Margins
Looking at the Profit Margin, with a value of 8.44%, MD belongs to the top of the industry, outperforming 89.00% of the companies in the same industry.
MD has a Operating Margin of 12.20%. This is amongst the best in the industry. MD outperforms 81.00% of its industry peers.
MD's Operating Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.2% | ||
| PM (TTM) | 8.44% | ||
| GM | N/A |
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MD is still creating some value.
MD has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MD has been increased compared to 5 years ago.
Compared to 1 year ago, MD has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.25 indicates that MD is not a great score, but indicates only limited risk for bankruptcy at the moment.
MD has a Altman-Z score (2.25) which is comparable to the rest of the industry.
MD has a debt to FCF ratio of 2.20. This is a good value and a sign of high solvency as MD would need 2.20 years to pay back of all of its debts.
MD's Debt to FCF ratio of 2.20 is fine compared to the rest of the industry. MD outperforms 80.00% of its industry peers.
A Debt/Equity ratio of 0.65 indicates that MD is somewhat dependend on debt financing.
The Debt to Equity ratio of MD (0.65) is comparable to the rest of the industry.
Even though the debt/equity ratio score it not favorable for MD, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.65 | ||
| Debt/FCF | 2.2 | ||
| Altman-Z | 2.25 |
ROIC/WACC1.13
WACC9.05%
2.3 Liquidity
MD has a Current Ratio of 1.83. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Current ratio value of 1.83, MD is doing good in the industry, outperforming 72.00% of the companies in the same industry.
MD has a Quick Ratio of 1.83. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
MD has a Quick ratio of 1.83. This is in the better half of the industry: MD outperforms 74.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.83 | ||
| Quick Ratio | 1.83 |
3. Growth
3.1 Past
MD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.92%, which is quite impressive.
Measured over the past years, MD shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -15.01% on average per year.
MD shows a decrease in Revenue. In the last year, the revenue decreased by -4.21%.
Measured over the past years, MD shows a small growth in Revenue. The Revenue has been growing by 2.49% on average per year.
EPS 1Y (TTM)56.92%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%52.27%
Revenue 1Y (TTM)-4.21%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-3.58%
3.2 Future
The Earnings Per Share is expected to grow by 3.76% on average over the next years.
MD is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.34% yearly.
EPS Next Y23.94%
EPS Next 2Y12.52%
EPS Next 3Y9.51%
EPS Next 5Y3.76%
Revenue Next Year-5.59%
Revenue Next 2Y-1.52%
Revenue Next 3Y0.03%
Revenue Next 5Y2.34%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 11.30 indicates a reasonable valuation of MD.
Based on the Price/Earnings ratio, MD is valued cheaply inside the industry as 88.00% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 25.89. MD is valued rather cheaply when compared to this.
MD is valuated correctly with a Price/Forward Earnings ratio of 12.22.
82.00% of the companies in the same industry are more expensive than MD, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of MD to the average of the S&P500 Index (34.59), we can say MD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.3 | ||
| Fwd PE | 12.22 |
4.2 Price Multiples
80.00% of the companies in the same industry are more expensive than MD, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MD indicates a rather cheap valuation: MD is cheaper than 90.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.34 | ||
| EV/EBITDA | 7.89 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MD has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.47
PEG (5Y)N/A
EPS Next 2Y12.52%
EPS Next 3Y9.51%
5. Dividend
5.1 Amount
MD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:MD (11/17/2025, 11:07:58 AM)
23.05
-0.1 (-0.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners97.31%
Inst Owner Change-2.06%
Ins Owners1.9%
Ins Owner Change9.91%
Market Cap2.01B
Revenue(TTM)1.92B
Net Income(TTM)162.19M
Analysts78.67
Price Target17.09 (-25.86%)
Short Float %3.22%
Short Ratio3.71
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.41%
Min EPS beat(2)21.14%
Max EPS beat(2)39.68%
EPS beat(4)4
Avg EPS beat(4)32.13%
Min EPS beat(4)21.14%
Max EPS beat(4)39.68%
EPS beat(8)7
Avg EPS beat(8)18.68%
EPS beat(12)7
Avg EPS beat(12)8.95%
EPS beat(16)9
Avg EPS beat(16)6.72%
Revenue beat(2)1
Avg Revenue beat(2)-0.77%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)0.42%
Revenue beat(4)2
Avg Revenue beat(4)-0.67%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.42%
Revenue beat(8)2
Avg Revenue beat(8)-2.24%
Revenue beat(12)2
Avg Revenue beat(12)-2.22%
Revenue beat(16)3
Avg Revenue beat(16)-2.43%
PT rev (1m)1.01%
PT rev (3m)-2.29%
EPS NQ rev (1m)13.06%
EPS NQ rev (3m)11.01%
EPS NY rev (1m)0%
EPS NY rev (3m)7.69%
Revenue NQ rev (1m)0.3%
Revenue NQ rev (3m)1.05%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.62%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.3 | ||
| Fwd PE | 12.22 | ||
| P/S | 1.04 | ||
| P/FCF | 7.34 | ||
| P/OCF | 6.92 | ||
| P/B | 2.25 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.89 |
EPS(TTM)2.04
EY8.85%
EPS(NY)1.89
Fwd EY8.18%
FCF(TTM)3.14
FCFY13.62%
OCF(TTM)3.33
OCFY14.45%
SpS22.08
BVpS10.23
TBVpS-4.36
PEG (NY)0.47
PEG (5Y)N/A
Graham Number21.67
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.37% | ||
| ROE | 18.21% | ||
| ROCE | 12.98% | ||
| ROIC | 10.25% | ||
| ROICexc | 13.79% | ||
| ROICexgc | 251.95% | ||
| OM | 12.2% | ||
| PM (TTM) | 8.44% | ||
| GM | N/A | ||
| FCFM | 14.22% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
ROICexc(3y)8.94%
ROICexc(5y)8.89%
ROICexgc(3y)78.23%
ROICexgc(5y)75.12%
ROCE(3y)9.91%
ROCE(5y)9.03%
ROICexgc growth 3Y26.95%
ROICexgc growth 5Y24.1%
ROICexc growth 3Y3.64%
ROICexc growth 5Y14.51%
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.87
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.65 | ||
| Debt/FCF | 2.2 | ||
| Debt/EBITDA | 2.24 | ||
| Cap/Depr | 72.01% | ||
| Cap/Sales | 0.86% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 112.59% | ||
| Profit Quality | 168.57% | ||
| Current Ratio | 1.83 | ||
| Quick Ratio | 1.83 | ||
| Altman-Z | 2.25 |
F-Score8
WACC9.05%
ROIC/WACC1.13
Cap/Depr(3y)81.28%
Cap/Depr(5y)89.11%
Cap/Sales(3y)1.42%
Cap/Sales(5y)1.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.92%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%52.27%
EPS Next Y23.94%
EPS Next 2Y12.52%
EPS Next 3Y9.51%
EPS Next 5Y3.76%
Revenue 1Y (TTM)-4.21%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-3.58%
Revenue Next Year-5.59%
Revenue Next 2Y-1.52%
Revenue Next 3Y0.03%
Revenue Next 5Y2.34%
EBIT growth 1Y42.45%
EBIT growth 3Y-5.51%
EBIT growth 5Y-4.62%
EBIT Next Year49.88%
EBIT Next 3Y15.85%
EBIT Next 5YN/A
FCF growth 1Y104.91%
FCF growth 3Y60.68%
FCF growth 5Y-11.42%
OCF growth 1Y73.9%
OCF growth 3Y39.11%
OCF growth 5Y-10.4%
PEDIATRIX MEDICAL GROUP INC / MD FAQ
What is the ChartMill fundamental rating of PEDIATRIX MEDICAL GROUP INC (MD) stock?
ChartMill assigns a fundamental rating of 5 / 10 to MD.
What is the valuation status of PEDIATRIX MEDICAL GROUP INC (MD) stock?
ChartMill assigns a valuation rating of 8 / 10 to PEDIATRIX MEDICAL GROUP INC (MD). This can be considered as Undervalued.
How profitable is PEDIATRIX MEDICAL GROUP INC (MD) stock?
PEDIATRIX MEDICAL GROUP INC (MD) has a profitability rating of 6 / 10.
How financially healthy is PEDIATRIX MEDICAL GROUP INC?
The financial health rating of PEDIATRIX MEDICAL GROUP INC (MD) is 5 / 10.
What is the expected EPS growth for PEDIATRIX MEDICAL GROUP INC (MD) stock?
The Earnings per Share (EPS) of PEDIATRIX MEDICAL GROUP INC (MD) is expected to grow by 23.94% in the next year.